par Renard, Marleen;Suciu, Stefan 
;Bertrand, Yves;Uyttebroeck, Anne;Ferster, Alina ;van der Werff Ten Bosch, Jutte;Mazingue, F;Plouvier, Emmanuel;Robert, Alain;Boutard, Patrick;Millot, Frédéric;Munzer, Martine;Mechinaud, F;Lescoeur, Brigitte;Baila, L.;Vandecruys, Els;Benoît, Yves;Philippet, Pierre;EORTC Children Leukaemia Group (CLG),
Référence Pediatric blood & cancer, 57, 1, page (119-125)
Publication Publié, 2011-07
;Bertrand, Yves;Uyttebroeck, Anne;Ferster, Alina ;van der Werff Ten Bosch, Jutte;Mazingue, F;Plouvier, Emmanuel;Robert, Alain;Boutard, Patrick;Millot, Frédéric;Munzer, Martine;Mechinaud, F;Lescoeur, Brigitte;Baila, L.;Vandecruys, Els;Benoît, Yves;Philippet, Pierre;EORTC Children Leukaemia Group (CLG), Référence Pediatric blood & cancer, 57, 1, page (119-125)
Publication Publié, 2011-07
Article révisé par les pairs
| Résumé : | Intensive chemotherapy has markedly improved the survival of children with acute lymphoblastic leukaemia (ALL) or lymphoblastic lymphoma (LL). Evaluation of late effects and analysis of factors contributing to their occurrence has become of major importance. Second neoplasm (SN) belongs to the most severe late events. |
